Emisphere Technologies (EMIS.OB) Extends Exclusive Agreement with Novo Nordisk (NVO) for Diabetes Treatment
Emisphere Technologies Inc. and Novo Nordisk A/S today announced their extended partnership to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® technology. The exclusive development and license agreement is in line with Novo Nordisk’s overall dedication to diabetes research. "This is an encouraging agreement on a promising technology for oral administration of proteins. We are delighted to continue working with Emisphere and their Eligen® Technology. It fits very well with Novo Nordisk's strategy within diabetes research," Peter Kurtzhals, senior vice president of Diabetes Research Unit at Novo Nordisk stated…